TWiV reveals that 2% of SARS-CoV-2‚ąípositive individuals carry 90% of the virus circulating in a college campus, and a nanoparticle vaccine that induces cross-reactive immunity against multiple pandemic and pre-emergent coronaviruses.

Daniel Griffin provides a clinical update on COVID-19, then we review an Ad5 vectored SARS-CoV-2 vaccine, reports on remdesivir and hydroxychloroquine, a drug repurposing study, why some patients infect many others, reducing viral transmission, and much more, including listener email.